چکیده (انگلیسی):

Background: In Th2 immune responses, TSLP is a key player by induction of OX40-ligand (OX40L) on dendritic
cells (DCs), which is the trigger to induce Th2 cell-mediated allergic cascade. Thus, TSLP-DC-OX40L
axis might be the principal pathway in the inflammatory cascades in atopic dermatitis and asthma. IL-33, which
is produced by epithelial cells, has been implicated in the Th2 immune responses and pathogenesis of the allergic
disorders. However, the role of IL-33 in the Th2-polarizing TSLP-DC-OX40L axis still remains largely elusive.
We focused on the ability of IL-33 to promote OX40L-mediated Th2 responses.
Methods: Purified human naïve or memory CD4+ T cells were stimulated with recombinant OX40L or TSLPtreated
DCs (TSLP-DCs) in the presence of IL-33, and the cytokine production by the primed T cells was examined.
We also performed immunohistochemical analyses for the expression of IL-33 in specimens of lymph
node and skin from the patients with atopic dermatitis.
Results: IL-33 remarkably enhanced TSLP-DCs-driven or OX40L-driven Th2 responses from naïve T cells
and the Th2 functional attributes of CRTH2+ CD4+ Th2 memory cells by the increased production of IL-5, IL-9,
and IL-13. In addition, IL-33 was expressed in the nuclei of epithelial cells in not only skin lesion but also lymph
nodes of the patient with atopic dermatitis, suggesting a specialized role in adaptive T cell-priming phase.
Conclusions: IL-33 works as a positive regulator of TSLP-DC-OX40L axis that initiates and maintains the Th2
cell-mediated inflammatory responses, and therefore, it would be a new therapeutic target for the treatment of
allergic disorders.